,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AATK,"AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77",ENSG00000181409,Apoptosis associated tyrosine kinase,17,81117295-81166077,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA009073,Enhanced,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 36.4;duodenum: 23.4,small intestine: 18.3,Group enriched,5.0,CACO-2: 35.4;SH-SY5Y: 15.1
1,AC009014.3,,ENSG00000271824,,5,136191468-136193134,Predicted membrane proteins,Evidence at transcript level,,,,,,"Liver cancer:1.63e-4 (favourable), Pancreatic cancer:6.13e-4 (favourable)",Tissue enhanced,Tissue enhanced,,duodenum: 13.2;kidney: 22.7,small intestine: 6.8,Cell line enhanced,,SCLC-21H: 2.0
2,AC009133.22,,ENSG00000277669,,16,29663279-29695144,Predicted secreted proteins,Evidence at protein level,HPA011887,Uncertain,,,,,Not detected,Tissue enhanced,,colon: 2.6;duodenum: 1.8;spleen: 1.0,lung: 0.4,Cell line enhanced,,BEWO: 44.0;EFO-21: 114.1;SH-SY5Y: 19.3
3,ACE,"ACE1, CD143, DCP1",ENSG00000159640,Angiotensin I converting enzyme,17,63477061-63498380,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002426, CAB002921, HPA029298, HPA069790",Enhanced,,Approved,Vesicles,,Expressed in all,Tissue enhanced,,duodenum: 178.9;small intestine: 291.6,testis: 83.7,Cell line enhanced,,ASC TERT1: 44.4;HUVEC TERT2: 28.2
4,ACY3,"ACY-3, HCBP1, MGC9740",ENSG00000132744,Aminoacylase 3,11,67642555-67650659,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039219, HPA048187",Enhanced,,,,Endometrial cancer:4.80e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 80.6;kidney: 53.3;small intestine: 78.6,"cervix, uterine: 16.1",Cell line enhanced,,CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2
5,ADAT3,TAD3,ENSG00000213638,"Adenosine deaminase, tRNA specific 3",19,1905378-1913447,Predicted intracellular proteins,Evidence at protein level,HPA058899,Uncertain,,Approved,Nucleus,"Head and neck cancer:6.13e-4 (favourable), Stomach cancer:6.98e-4 (favourable)",Expressed in all,Tissue enhanced,,duodenum: 7.5,small intestine: 5.3,Cell line enhanced,,HEK93: 11.3
6,ADGRG4,"GPR112, PGR17, RP1-299I16",ENSG00000156920,Adhesion G protein-coupled receptor G4,X,136300963-136416888,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA035324,Uncertain,,,,,Not detected,Tissue enhanced,,duodenum: 2.5;small intestine: 1.7,fallopian tube: 0.5,Not detected,,
7,ADH1C,ADH3,ENSG00000248144,"Alcohol dehydrogenase 1C (class I), gamma polypeptide",4,99336492-99353027,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,,Supported,Plasma membrane<br>Cytosol,"Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 508.1;liver: 888.0;stomach: 477.4,colon: 276.3,Cell line enhanced,,ASC TERT1: 2.5;HSkMC: 7.7
8,AKR1B10,"AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI",ENSG00000198074,Aldo-keto reductase family 1 member B10,7,134527592-134541408,Predicted intracellular proteins,Evidence at protein level,"HPA020280, CAB070163, HPA073633",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable)",Tissue enhanced,Tissue enhanced,,duodenum: 635.9;gallbladder: 283.3;small intestine: 387.2;stomach: 414.4,esophagus: 89.8,Group enriched,74.0,A549: 2731.1;Hep G2: 580.9
9,ANKS4B,"FLJ38819, HARP",ENSG00000175311,Ankyrin repeat and sterile alpha motif domain containing 4B,16,21233665-21253845,Predicted intracellular proteins,Evidence at protein level,HPA043523,Approved,,Approved,Nucleoplasm<br>Cytosol,,Group enriched,Tissue enhanced,,duodenum: 9.0;rectum: 7.8;small intestine: 12.9,colon: 6.8,Group enriched,10.0,CACO-2: 1.1;HDLM-2: 3.2;Hep G2: 5.5
10,ANO9,"PIG5, TMEM16J, TP53I5",ENSG00000185101,Anoctamin 9,11,417933-442011,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA039948, HPA040112",Approved,,Uncertain,Golgi apparatus,Urothelial cancer:8.81e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 31.6;small intestine: 30.9,skin: 21.6,Cell line enhanced,,BEWO: 8.6;CAPAN-2: 24.1;HaCaT: 14.1;RPMI-8226: 13.6
11,AQP11,,ENSG00000178301,Aquaporin 11,11,77589391-77610355,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA042879,Approved,,Approved,Nucleoplasm<br>Vesicles,Ovarian cancer:9.89e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 24.1;small intestine: 23.1,adrenal gland: 10.0,Cell line enhanced,,Hep G2: 7.7
12,ARHGDIG,RHOGDI-3,ENSG00000242173,Rho GDP dissociation inhibitor gamma,16,268727-283010,Predicted intracellular proteins,Evidence at protein level,HPA078260,,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 131.1;duodenum: 44.2,small intestine: 17.9,Cell line enhanced,,HEK93: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7
13,ARHGEF16,"GEF16, NBR",ENSG00000130762,Rho guanine nucleotide exchange factor 16,1,3454426-3481113,Predicted intracellular proteins,Evidence at protein level,HPA010609,Approved,,,,"Renal cancer:1.24e-10 (favourable), Liver cancer:1.82e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 42.1,small intestine: 35.9,Cell line enhanced,,CAPAN-2: 48.8;MCF7: 24.6;SK-BR-3: 25.6
14,B3GNT8,"B3GALT7, beta3Gn-T8, BGALT15",ENSG00000177191,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8",19,41425359-41428730,Predicted secreted proteins,Evidence at protein level,HPA043669,Enhanced,,,,"Pancreatic cancer:9.31e-6 (favourable), Endometrial cancer:4.11e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 15.5;small intestine: 16.8,esophagus: 10.7,Cell line enhanced,,HMC-1: 5.7;HUVEC TERT2: 2.9;U-937: 4.3
15,BAIAP2L2,"FLJ22582, pinkbar",ENSG00000128298,BAI1 associated protein 2 like 2,22,38084889-38110670,Predicted intracellular proteins,Evidence at protein level,HPA003043,Approved,,,,,Expressed in all,Tissue enhanced,,duodenum: 107.2;small intestine: 97.5,gallbladder: 27.4,Cell line enhanced,,RPTEC TERT1: 22.3;SK-MEL-30: 29.5;WM-115: 29.0
16,BCL2L15,"Bfk, C1orf178, FLJ22588",ENSG00000188761,BCL2 like 15,1,113878168-113887547,Predicted intracellular proteins,Evidence at protein level,"HPA029732, HPA029733",Enhanced,,,,Endometrial cancer:5.63e-4 (favourable),Tissue enhanced,Tissue enhanced,,colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3,stomach: 24.0,Cell line enhanced,,CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6
17,BCO1,"BCDO, BCDO1, BCMO, BCMO1, FLJ10730",ENSG00000135697,Beta-carotene oxygenase 1,16,81238448-81291142,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA043811,,,Uncertain,Actin filaments<br>Microtubule organizing center,,Mixed,Tissue enhanced,,duodenum: 8.7;small intestine: 14.8,kidney: 3.3,Cell line enhanced,,A549: 9.9;EFO-21: 7.6;HAP1: 3.2;NTERA-2: 4.4;RPTEC TERT1: 6.2
18,C1QTNF12,"ADIPOLIN, C1QDC2, CTRP12, FAM132A, MGC105127",ENSG00000184163,C1q and tumor necrosis factor related protein 12,1,1242446-1246722,Predicted secreted proteins,Evidence at protein level,HPA024107,Approved,,Approved,Vesicles,,Mixed,Tissue enhanced,,duodenum: 6.9;small intestine: 7.3,colon: 2.1,Group enriched,5.0,EFO-21: 3.9;U-2 OS: 4.3
19,C6orf222,DKFZp779B1540,ENSG00000189325,Chromosome 6 open reading frame 222,6,36315757-36336885,Predicted intracellular proteins,Evidence at protein level,"HPA038407, HPA058189",Uncertain,,,,,Group enriched,Tissue enhanced,,duodenum: 24.7;small intestine: 26.4,rectum: 6.2,Not detected,,
20,C8orf86,FLJ43582,ENSG00000196166,Chromosome 8 open reading frame 86,8,38510834-38528662,Predicted intracellular proteins,Evidence at transcript level,HPA025066,Uncertain,,,,,Not detected,Tissue enhanced,,duodenum: 1.0,small intestine: 0.5,Not detected,,
21,CALML4,"MGC4809, NY-BR-20",ENSG00000129007,Calmodulin like 4,15,68190705-68206110,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA051109,Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 79.8;small intestine: 74.4,colon: 58.5,Mixed,,
22,CBLC,"CBL-3, CBL-SL, RNF57",ENSG00000142273,Cbl proto-oncogene C,19,44777869-44800634,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008087, HPA035266",Approved,,Approved,Nucleoplasm,Renal cancer:3.11e-6 (favourable),Mixed,Tissue enhanced,,duodenum: 52.5;skin: 41.9;small intestine: 44.0,colon: 21.4,Cell line enhanced,,A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
23,CCL15,"HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3",ENSG00000275718,C-C motif chemokine ligand 15,17,35996440-36002038,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA058608,,,Approved,Golgi apparatus<br>Vesicles,Urothelial cancer:3.02e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 21.5;rectum: 30.6;small intestine: 26.6,colon: 18.9,Cell line enriched,12.0,Hep G2: 22.7
24,CES3,"ES31, FLJ21736",ENSG00000172828,Carboxylesterase 3,16,66961237-66975148,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041008, HPA041307",Approved,,Approved,Nuclear membrane<br>Endoplasmic reticulum,Liver cancer:7.26e-5 (favourable),Mixed,Tissue enhanced,,colon: 37.2;duodenum: 30.5;rectum: 34.1,small intestine: 26.6,Cell line enhanced,,AN3-CA: 7.1
25,CHN2,"ARHGAP3, RhoGAP3",ENSG00000106069,Chimerin 2,7,29122274-29514328,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018989,Approved,,Approved,Nucleus,,Mixed,Tissue enhanced,,duodenum: 74.8;small intestine: 68.4,cerebral cortex: 31.7,Cell line enhanced,,HEL: 34.5;HMC-1: 60.7
26,CHST6,MCDC1,ENSG00000183196,Carbohydrate sulfotransferase 6,16,75472052-75495384,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 16.3;duodenum: 10.6;small intestine: 10.9",cerebral cortex: 7.9,Cell line enhanced,,AN3-CA: 10.8;CAPAN-2: 11.4;NTERA-2: 6.2;U-2 OS: 8.0;WM-115: 6.7
27,CYP2C19,"CPCJ, CYP2C, P450IIC19",ENSG00000165841,Cytochrome P450 family 2 subfamily C member 19,10,94762624-94853260,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015066,Supported,,,,,Not detected,Tissue enhanced,,duodenum: 48.3;liver: 125.6,small intestine: 20.7,Not detected,,
28,CYP2S1,,ENSG00000167600,Cytochrome P450 family 2 subfamily S member 1,19,41193049-41207539,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA049227, HPA069248",Approved,,Approved,Endoplasmic reticulum,Renal cancer:1.60e-6 (unfavourable),Expressed in all,Tissue enhanced,,duodenum: 96.7;small intestine: 68.6;stomach: 111.7,colon: 25.9,Cell line enhanced,,A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
29,CYP2W1,"FLJ20359, MGC34287",ENSG00000073067,Cytochrome P450 family 2 subfamily W member 1,7,983199-989640,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA012753,Uncertain,,,,Urothelial cancer:5.85e-4 (unfavourable),Group enriched,Tissue enhanced,,adrenal gland: 5.5;duodenum: 6.2;skin: 9.7,placenta: 1.4,Group enriched,7.0,CACO-2: 11.2;Hep G2: 33.8
30,CYP3A5,"CP35, P450PCN3, PCN3",ENSG00000106258,Cytochrome P450 family 3 subfamily A member 5,7,99648194-99679998,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,Liver cancer:3.72e-5 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 114.8;liver: 93.2;small intestine: 187.6,stomach: 77.7,Cell line enhanced,,A549: 2.5;CACO-2: 7.9;CAPAN-2: 5.7;Hep G2: 5.0
31,CYP4F12,,ENSG00000186204,Cytochrome P450 family 4 subfamily F member 12,19,15672757-15697174,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058960,Approved,,,,"Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable)",Group enriched,Tissue enhanced,,duodenum: 36.2;small intestine: 42.3,skin: 22.3,Cell line enhanced,,CAPAN-2: 14.8;HaCaT: 26.3;Karpas-707: 14.2;SiHa: 6.0
32,DAB1,,ENSG00000173406,"DAB1, reelin adaptor protein",1,56994778-58546734,Predicted intracellular proteins,Evidence at protein level,"CAB032329, HPA052033, HPA067495",Enhanced,,Supported,Vesicles,,Mixed,Tissue enhanced,,duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8,prostate: 6.4,Cell line enhanced,,fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3
33,DDC,AADC,ENSG00000132437,Dopa decarboxylase,7,50458436-50565457,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017742,Enhanced,,Approved,Actin filaments,,Mixed,Tissue enhanced,,duodenum: 155.2;kidney: 320.9;small intestine: 180.5,adrenal gland: 63.8,Group enriched,9.0,CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
34,DGAT1,"ARGP1, DGAT",ENSG00000185000,Diacylglycerol O-acyltransferase 1,8,144314584-144326910,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,CAB032853,Enhanced,,Approved,Nucleoli<br>Endoplasmic reticulum,,Expressed in all,Tissue enhanced,,duodenum: 71.3;small intestine: 75.1,adipose tissue: 20.0,Cell line enhanced,,PC-3: 35.6
35,DKK4,,ENSG00000104371,Dickkopf WNT signaling pathway inhibitor 4,8,42374068-42377232,Predicted secreted proteins,Evidence at protein level,HPA052916,Approved,,,,,Tissue enriched,Tissue enhanced,,duodenum: 2.4;esophagus: 5.4;testis: 2.7,urinary bladder: 1.4,Cell line enriched,9.0,Hep G2: 1.4
36,DMBT1,"GP340, muclin, SALSA",ENSG00000187908,Deleted in malignant brain tumors 1,10,122560665-122643736,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA040778,Enhanced,,Approved,Microtubule organizing center,Endometrial cancer:1.43e-4 (favourable),Group enriched,Tissue enhanced,,duodenum: 816.7;small intestine: 277.6,salivary gland: 136.1,Cell line enhanced,,hTERT-HME1: 3.5;LHCN-M2: 7.8;RH-30: 20.9
37,DQX1,FLJ23757,ENSG00000144045,DEAQ-box RNA dependent ATPase 1,2,74518131-74526336,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039158,Enhanced,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 14.4;small intestine: 13.5,colon: 5.5,Cell line enhanced,,HBEC3-KT: 4.2;Hep G2: 11.5;hTCEpi: 4.3
38,ENTPD8,"NTPDase-8, UNQ2492",ENSG00000188833,Ectonucleoside triphosphate diphosphohydrolase 8,9,137434364-137441816,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA021509,Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Stomach cancer:7.17e-4 (favourable),Mixed,Tissue enhanced,,colon: 21.7;duodenum: 28.7;small intestine: 31.6,rectum: 12.5,Cell line enhanced,,CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
39,ESCO2,"EFO2, RBS",ENSG00000171320,Establishment of sister chromatid cohesion N-acetyltransferase 2,8,27771949-27812640,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA027243, HPA053679",,,Supported,Nucleus<br>Golgi apparatus,Colorectal cancer:1.04e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 11.2,testis: 10.4,Mixed,,
40,EXOC3L4,C14orf73,ENSG00000205436,Exocyst complex component 3 like 4,14,103100144-103110559,Predicted intracellular proteins,Evidence at protein level,HPA043661,Approved,,,,Colorectal cancer:1.43e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,duodenum: 19.2,small intestine: 10.7,Cell line enhanced,,HDLM-2: 3.5;HEL: 3.4;Hep G2: 1.8;RPMI-8226: 1.8
41,FAM3B,"2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44",ENSG00000183844,Family with sequence similarity 3 member B,21,41304212-41357431,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA015885, HPA029777",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,duodenum: 162.1;small intestine: 166.8,stomach: 124.0,Cell line enhanced,,CACO-2: 16.2;CAPAN-2: 10.8;Hep G2: 22.1;RPMI-8226: 62.5
42,FAM83E,FLJ20200,ENSG00000105523,Family with sequence similarity 83 member E,19,48600810-48614854,Predicted intracellular proteins,Evidence at protein level,HPA049305,Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 30.8;small intestine: 35.3;stomach: 40.7,colon: 22.5,Cell line enhanced,,CAPAN-2: 2.9
43,FEV,Pet-1,ENSG00000163497,"FEV, ETS transcription factor",2,218981087-218985657,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA067679,,Supported,Supported,Nuclear speckles,Pancreatic cancer:4.85e-4 (favourable),Group enriched,Tissue enhanced,,adrenal gland: 2.1;duodenum: 2.9;prostate: 1.9;stomach: 2.4,small intestine: 1.6,Group enriched,6.0,HMC-1: 22.4;SH-SY5Y: 34.6
44,FLJ22763,,ENSG00000241224,Uncharacterized LOC401081,3,109118252-109150514,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 97.6;small intestine: 94.5,kidney: 19.5,Cell line enhanced,,CACO-2: 1.0
45,FUT2,"SE, Se2, SEC2, sej",ENSG00000176920,Fucosyltransferase 2,19,48695971-48705950,"Blood group antigen proteins, Enzymes, Predicted membrane proteins",Evidence at protein level,HPA014402,Uncertain,,Uncertain,Plasma membrane<br>Cytosol,Head and neck cancer:5.83e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 51.4,stomach: 32.2,Cell line enriched,6.0,CAPAN-2: 68.6
46,GAGE12B,,ENSG00000236737,G antigen 12B,X,49529869-49529985,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,duodenum: 1.2,spleen: 0.4,Group enriched,20.0,PC-3: 2.6;U-2197: 1.4
47,GAL3ST1,CST,ENSG00000128242,Galactose-3-O-sulfotransferase 1,22,30554635-30574587,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA001220,Approved,,Approved,Vesicles,Renal cancer:1.79e-4 (unfavourable),Tissue enriched,Tissue enhanced,,cerebral cortex: 18.0;duodenum: 23.2;small intestine: 27.0,kidney: 10.1,Cell line enhanced,,A549: 25.1;EFO-21: 13.7
48,GATA4,,ENSG00000136574,GATA binding protein 4,8,11676959-11760002,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB013125, HPA073899",Uncertain,,Supported,Nuclear bodies,,Tissue enhanced,Tissue enhanced,,duodenum: 72.5;heart muscle: 59.0;ovary: 111.8,testis: 51.5,Cell line enhanced,,HEK93: 11.9;Hep G2: 21.2;HHSteC: 31.6;SH-SY5Y: 45.2
49,GATA5,"bB379O24.1, GATAS",ENSG00000130700,GATA binding protein 5,20,62463497-62475970,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA067583,,,Approved,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,duodenum: 11.4;small intestine: 11.0;testis: 8.7,stomach: 7.5,Cell line enhanced,,HEL: 2.6;K-562: 4.2;SiHa: 2.1;T-47d: 4.4
50,GDA,,ENSG00000119125,Guanine deaminase,9,72114595-72257193,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA019352, HPA024099, HPA030387",Enhanced,,Approved,Nucleus,Renal cancer:2.66e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1,kidney: 43.6,Cell line enhanced,,A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2
51,GHRH,GHRF,ENSG00000118702,Growth hormone releasing hormone,20,37251082-37261835,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,adrenal gland: 1.4;duodenum: 3.4,small intestine: 1.2,Cell line enhanced,,NTERA-2: 2.0;U-266/84: 5.4
52,GIMD1,,ENSG00000250298,GIMAP family P-loop NTPase domain containing 1,4,106357485-106368825,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,duodenum: 28.6;small intestine: 18.0,gallbladder: 4.9,Not detected,,
53,GLOD5,,ENSG00000171433,Glyoxalase domain containing 5,X,48761750-48773648,Predicted intracellular proteins,Evidence at protein level,HPA010667,Uncertain,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 10.8;kidney: 11.0;small intestine: 10.7,epididymis: 6.8,Cell line enhanced,,MCF7: 1.6
54,GLTPD2,,ENSG00000182327,Glycolipid transfer protein domain containing 2,17,4788959-4790390,Predicted secreted proteins,Evidence at protein level,"HPA058295, HPA065267",Uncertain,,Approved,Vesicles,,Tissue enriched,Tissue enhanced,,duodenum: 11.0;kidney: 12.8;liver: 13.8,small intestine: 7.2,Cell line enhanced,,CACO-2: 8.6;Hep G2: 9.4
55,GLYCTK,"HBEBP2, HBEBP4",ENSG00000168237,Glycerate kinase,3,52287089-52293476,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA006913,Approved,,Approved,Golgi apparatus<br>Cytosol<br>Rods & Rings,Head and neck cancer:1.64e-4 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 38.3;liver: 60.6,small intestine: 31.8,Expressed in all,,
56,GNAT3,"GDCA, gustducin",ENSG00000214415,G protein subunit alpha transducin 3,7,80458671-80512020,Predicted intracellular proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,duodenum: 1.9;small intestine: 1.4,testis: 0.5,Cell line enriched,8.0,SCLC-21H: 3.9
57,GNG13,"G(gamma)13, h2-35",ENSG00000127588,G protein subunit gamma 13,16,798041-800733,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA046272,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.5;duodenum: 1.4;small intestine: 1.4,colon: 0.7,Cell line enhanced,,CACO-2: 8.6;HEK93: 8.3;MCF7: 10.0
58,GOLT1A,"CGI-141, FLJ42654, GOT1, MGC62027, YMR292W",ENSG00000174567,Golgi transport 1A,1,204198160-204214092,Predicted membrane proteins,Evidence at protein level,,,,,,"Renal cancer:6.35e-5 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Glioma:5.49e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,duodenum: 40.3;liver: 79.1;small intestine: 42.3,parathyroid gland: 28.1,Cell line enhanced,,CACO-2: 12.3;CAPAN-2: 14.9;Hep G2: 14.6;MCF7: 27.7;RT4: 18.6;SK-BR-3: 17.2
59,GPR35,,ENSG00000178623,G protein-coupled receptor 35,2,240605431-240631259,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,"Renal cancer:2.59e-5 (unfavourable), Lung cancer:5.86e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,duodenum: 41.4;small intestine: 42.3,colon: 18.4,Cell line enhanced,,CACO-2: 17.1;CAPAN-2: 45.0;HDLM-2: 16.3;Hep G2: 22.7;HMC-1: 27.8
60,GSDMB,"GSDML, PRO2521",ENSG00000073605,Gasdermin B,17,39904595-39919854,"Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB013681, HPA023925, HPA052407",Enhanced,,,,"Renal cancer:5.13e-11 (unfavourable), Urothelial cancer:5.91e-9 (favourable), Cervical cancer:3.41e-5 (favourable)",Expressed in all,Tissue enhanced,,duodenum: 67.0;small intestine: 85.1,rectum: 62.6,Cell line enriched,7.0,SK-BR-3: 342.4
61,HIST1H2BH,"H2B/j, H2BFJ",ENSG00000275713,Histone cluster 1 H2B family member h,6,26251651-26253710,Predicted intracellular proteins,Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,Head and neck cancer:7.52e-4 (unfavourable),Mixed,Tissue enhanced,,duodenum: 3.0,small intestine: 1.2,Cell line enhanced,,U-266/70: 12.9
62,HKDC1,"FLJ22761, FLJ37767",ENSG00000156510,Hexokinase domain containing 1,10,69220303-69267559,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011956, HPA064198, HPA064230",Approved,,Enhanced,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 53.1;small intestine: 52.3,thyroid gland: 15.2,Group enriched,6.0,A549: 35.7;CACO-2: 46.7;CAPAN-2: 96.8;EFO-21: 31.5;Hep G2: 22.5;RPTEC TERT1: 61.4
63,HNF1A,"HNF1, LFB1, MODY3, TCF1",ENSG00000135100,HNF1 homeobox A,12,120978543-121002512,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB010430, HPA035231",Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,duodenum: 15.5;kidney: 10.6;small intestine: 15.7,liver: 6.3,Group enriched,7.0,A549: 8.0;CACO-2: 24.3;Hep G2: 22.1
64,HRASLS2,FLJ20556,ENSG00000133328,HRAS like suppressor 2,11,63552770-63563383,Predicted membrane proteins,Evidence at protein level,HPA058997,Approved,,Approved,Mitochondria,"Pancreatic cancer:5.27e-5 (unfavourable), Cervical cancer:6.87e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 67.6;small intestine: 46.5,rectum: 14.4,Cell line enriched,7.0,U-266/70: 97.6
65,HSD17B2,"HSD17, SDR9C2",ENSG00000086696,Hydroxysteroid 17-beta dehydrogenase 2,16,82035004-82098534,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021826, HPA050235",Enhanced,,Approved,Endoplasmic reticulum,Urothelial cancer:3.83e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 430.9;placenta: 552.6,small intestine: 199.4,Cell line enhanced,,BJ hTERT+: 47.0;Hep G2: 32.2;RT4: 77.0;TIME: 44.0
66,HTR3E,,ENSG00000186038,5-hydroxytryptamine receptor 3E,3,184097064-184106995,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA049764,Enhanced,,,,,Not detected,Tissue enhanced,,duodenum: 1.0,small intestine: 0.8,Cell line enriched,6.0,RH-30: 1.3
67,HTR4,5-HT4,ENSG00000164270,5-hydroxytryptamine receptor 4,5,148451032-148677235,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040591,Approved,,,,,Not detected,Tissue enhanced,,duodenum: 4.8;small intestine: 10.0,rectum: 3.1,Not detected,,
68,ITPKA,"IP3-3KA, IP3KA",ENSG00000137825,Inositol-trisphosphate 3-kinase A,15,41493393-41503551,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040454,Enhanced,Approved,Approved,Vesicles,"Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8,stomach: 8.9,Cell line enhanced,,Hep G2: 22.6
69,KCNK10,"K2p10.1, PPP1R97, TREK-2, TREK2",ENSG00000100433,Potassium two pore domain channel subfamily K member 10,14,88180103-88326907,Predicted membrane proteins,Evidence at protein level,HPA030462,Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 5.6;duodenum: 5.1,"small intestine,stomach: 2.7",Cell line enhanced,,AF22: 1.0;REH: 1.6;SCLC-21H: 3.7
70,KCNK16,"K2p16.1, TALK-1, TALK1",ENSG00000095981,Potassium two pore domain channel subfamily K member 16,6,39314698-39322968,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,duodenum: 3.8;pancreas: 5.4;stomach: 12.4,thyroid gland: 1.7,Cell line enriched,511.0,SCLC-21H: 157.3
71,KRT20,"CK20, K20, MGC35423",ENSG00000171431,Keratin 20,17,40875941-40885227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000032, HPA024309, HPA024684, HPA027236",Enhanced,,Supported,Cytosol,"Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable)",Group enriched,Tissue enhanced,,colon: 356.1;duodenum: 252.4;rectum: 295.3;small intestine: 499.6,stomach: 82.3,Cell line enhanced,,BEWO: 1.0;RT4: 2.3
72,LBX2,,ENSG00000179528,Ladybird homeobox 2,2,74497517-74503316,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA044257,Uncertain,,Approved,Nucleus<br>Midbody,,Mixed,Tissue enhanced,,duodenum: 5.3;small intestine: 5.3,stomach: 3.0,Cell line enhanced,,Hep G2: 14.9
73,LCN15,"PRO6093, UNQ2541",ENSG00000177984,Lipocalin 15,9,136759634-136766255,Predicted secreted proteins,Evidence at protein level,HPA060584,Enhanced,,,,,Tissue enriched,Tissue enhanced,,duodenum: 12.1;seminal vesicle: 5.0;small intestine: 4.0,colon: 2.8,Group enriched,14.0,Hep G2: 11.9;SCLC-21H: 3.0
74,LGALS4,GAL4,ENSG00000171747,Galectin 4,19,38801671-38813364,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB025653, HPA031184, HPA031185, HPA031186",Enhanced,,Uncertain,Plasma membrane,"Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)",Group enriched,Tissue enhanced,,colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5,gallbladder: 138.8,Cell line enhanced,,CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0
75,LHB,"CGB4, hLHB, LSH-B",ENSG00000104826,Luteinizing hormone beta polypeptide,19,49015980-49017081,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB022241, CAB022707, HPA038925",Supported,,Approved,Cytosol,Pancreatic cancer:6.78e-4 (unfavourable),Mixed,Tissue enhanced,,duodenum: 3.2;pancreas: 4.8;testis: 2.9,"adrenal gland,skin,small intestine: 0.7",Mixed,,
76,LMX1A,"LMX1, LMX1.1",ENSG00000162761,LIM homeobox transcription factor 1 alpha,1,165201867-165356715,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA028051, HPA030088",,,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,,Not detected,Tissue enhanced,,duodenum: 1.0;testis: 2.2,"adipose tissue,rectum,small intestine: 0.6",Cell line enriched,11.0,SCLC-21H: 1.0
77,LRRC66,,ENSG00000188993,Leucine rich repeat containing 66,4,51993702-52017620,Predicted membrane proteins,Evidence at transcript level,"HPA014549, HPA027839",Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 22.5;small intestine: 20.5,rectum: 6.4,Cell line enhanced,,ASC TERT1: 1.0;CAPAN-2: 1.8
78,LRRC75A,"C17orf76, FAM211A, FLJ35696",ENSG00000181350,Leucine rich repeat containing 75A,17,16441577-16492153,Predicted intracellular proteins,Evidence at protein level,HPA028528,Uncertain,,,,Pancreatic cancer:7.46e-5 (favourable),Mixed,Tissue enhanced,,duodenum: 11.0,small intestine: 11.0,Cell line enhanced,,HEL: 6.2
79,MGAM,MGA,ENSG00000257335,Maltase-glucoamylase,7,141907813-142106747,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA002270,Enhanced,,,,Renal cancer:6.16e-5 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 59.4;small intestine: 97.2,epididymis: 31.1,Cell line enhanced,,A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
80,MINOS1-NBL1,,ENSG00000270136,MINOS1-NBL1 readthrough,1,19596979-19658056,Predicted secreted proteins,Evidence at transcript level,HPA007394,Uncertain,,,,,Not detected,Tissue enhanced,,duodenum: 16.2;small intestine: 17.2,adipose tissue: 13.7,Cell line enhanced,,A-431: 25.2;BJ: 49.3;EFO-21: 25.9;HDLM-2: 32.5
81,MLXIPL,"bHLHd14, CHREBP, MIO, MONDOB, WBSCR14, WS-bHLH",ENSG00000009950,MLX interacting protein like,7,73593194-73624543,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA064640,,,Supported,Nucleus,,Tissue enriched,Tissue enhanced,,adipose tissue: 60.8;duodenum: 58.7,liver: 47.2,Cell line enhanced,,Hep G2: 33.0;K-562: 13.2;SCLC-21H: 29.5;T-47d: 10.7
82,MME,"CALLA, CD10, NEP",ENSG00000196549,Membrane metalloendopeptidase,3,155024124-155183729,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000013, HPA052583, HPA056072",Enhanced,,,,,Mixed,Tissue enhanced,,duodenum: 428.2;kidney: 384.2;small intestine: 401.5,prostate: 162.5,Cell line enhanced,,ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
83,MNX1,"HB9, HLXB9, HOXHB9, SCRA1",ENSG00000130675,Motor neuron and pancreas homeobox 1,7,156994051-157010651,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071717,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 7.3;small intestine: 6.7,colon: 3.7,Cell line enhanced,,AN3-CA: 16.0;EFO-21: 15.3;RPMI-8226: 25.9;SCLC-21H: 22.6
84,MS4A18,,ENSG00000214782,Membrane spanning 4-domains A18,11,60729304-60744212,Predicted membrane proteins,Evidence at transcript level,HPA045121,Approved,,,,,Not detected,Tissue enhanced,,breast: 10.3;duodenum: 23.9,small intestine: 4.0,Not detected,,
85,MS4A8,"CD20L5, MS4A4, MS4A8B",ENSG00000166959,Membrane spanning 4-domains A8,11,60699574-60715811,Predicted membrane proteins,Evidence at protein level,"HPA007318, HPA007319",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 186.5;fallopian tube: 226.5;small intestine: 210.9,stomach: 49.1,Cell line enhanced,,SCLC-21H: 1.1
86,MT1B,"MT1, MT1Q",ENSG00000169688,Metallothionein 1B,16,56651899-56653204,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,duodenum: 1.3;liver: 3.2,appendix: 0.5,Not detected,,
87,MUC3A,MUC3,ENSG00000169894,"Mucin 3A, cell surface associated",7,100949555-100968346,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010871,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1,rectum: 13.1,Cell line enhanced,,CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
88,MYO7B,,ENSG00000169994,Myosin VIIB,2,127535802-127637729,Predicted intracellular proteins,Evidence at protein level,HPA039131,Enhanced,,,,Renal cancer:1.25e-4 (favourable),Group enriched,Tissue enhanced,,duodenum: 113.9;small intestine: 92.1,colon: 35.2,Cell line enriched,17.0,MOLT-4: 228.8
89,NAGS,"AGAS, ARGA, NAT7",ENSG00000161653,N-acetylglutamate synthase,17,44004546-44009063,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA027300,,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,duodenum: 14.8;small intestine: 13.6,liver: 5.0,Cell line enhanced,,HHSteC: 4.0;TIME: 5.0;U-87 MG: 8.7
90,NAPRT,"NAPRT1, PP3856",ENSG00000147813,Nicotinate phosphoribosyltransferase,8,143574785-143578649,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023739, HPA024017, CAB068206, CAB068207",Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,Renal cancer:6.28e-4 (favourable),Expressed in all,Tissue enhanced,,duodenum: 21.4;small intestine: 20.7,bone marrow: 9.6,Cell line enhanced,,CAPAN-2: 33.3;SK-BR-3: 30.1
91,NDUFC2-KCTD14,,ENSG00000259112,NDUFC2-KCTD14 readthrough,11,78016971-78079865,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038873, HPA056195",Approved,,Supported,Mitochondria,,Not detected,Tissue enhanced,,duodenum: 5.0,stomach: 2.5,Cell line enhanced,,CACO-2: 7.9;EFO-21: 7.0;U-2 OS: 12.0
92,NEUROD1,"BETA2, BHF-1, bHLHa3, MODY6, NEUROD",ENSG00000162992,Neuronal differentiation 1,2,181673088-181680876,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003278, CAB022450",Approved,,,,Glioma:6.83e-5 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.9;duodenum: 6.0;small intestine: 4.4;stomach: 4.9,pancreas: 1.8,Cell line enriched,79.0,SCLC-21H: 331.4
93,NEUROG3,"Atoh5, bHLHa7, Math4B, ngn3",ENSG00000122859,Neurogenin 3,10,69571698-69573238,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA039785,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 2.8;small intestine: 1.3,"colon,rectum: 0.4",Group enriched,19.0,HMC-1: 1.7;THP-1: 7.1
94,NKX6-3,FLJ25169,ENSG00000165066,NK6 homeobox 3,8,41645178-41650669,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA042790,Uncertain,,,,,Group enriched,Tissue enhanced,,duodenum: 17.3;stomach: 50.6,parathyroid gland: 7.3,Group enriched,7.0,Daudi: 4.2;THP-1: 1.8
95,NPC1L1,,ENSG00000015520,NPC1 like intracellular cholesterol transporter 1,7,44512535-44541315,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"CAB070127, CAB070128",Enhanced,,,,,Group enriched,Tissue enhanced,,duodenum: 57.1;small intestine: 57.9,liver: 14.2,Group enriched,7.0,CACO-2: 5.9;Hep G2: 12.2;SCLC-21H: 17.4
96,NR0B2,SHP,ENSG00000131910,Nuclear receptor subfamily 0 group B member 2,1,26911489-26913966,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,duodenum: 78.6;liver: 48.8,small intestine: 28.9,Cell line enriched,19.0,Hep G2: 53.5
97,OLFM4,"GC1, GW112, OlfD",ENSG00000102837,Olfactomedin 4,13,53028759-53052057,Predicted secreted proteins,Evidence at protein level,HPA077718,Enhanced,,,,Breast cancer:8.77e-4 (favourable),Group enriched,Tissue enhanced,,duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8,colon: 445.0,Cell line enhanced,,BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9
98,OMP,,ENSG00000254550,Olfactory marker protein,11,77102840-77103331,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,duodenum: 2.7;small intestine: 2.8,rectum: 2.0,Not detected,,
99,ONECUT2,OC-2,ENSG00000119547,One cut homeobox 2,18,57435685-57491297,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057058,Enhanced,,Supported,Nucleoplasm<br>Actin filaments,,Group enriched,Tissue enhanced,,duodenum: 10.4;gallbladder: 16.3,liver: 4.5,Cell line enhanced,,HDLM-2: 19.1;HeLa: 8.5;SCLC-21H: 12.1
100,PAX4,MODY9,ENSG00000106331,Paired box 4,7,127610292-127618114,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,duodenum: 1.0;rectum: 1.1,"small intestine,testis: 0.6",Cell line enriched,73.0,SCLC-21H: 15.3
101,PDZD3,"FLJ22756, IKEPP, PDZK2",ENSG00000172367,PDZ domain containing 3,11,119185457-119190223,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 17.3;kidney: 10.8;small intestine: 21.2,rectum: 6.7,Not detected,,
102,PIGR,,ENSG00000162896,Polymeric immunoglobulin receptor,1,206928518-206946466,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA006154, CAB009454, HPA012012",Enhanced,,,,"Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable)",Tissue enhanced,Tissue enhanced,,colon: 1688.0;duodenum: 2659.3,rectum: 1335.9,Cell line enriched,7.0,EFO-21: 33.8
103,PLS1,"I-plastin, Plastin-1",ENSG00000120756,Plastin 1,3,142596387-142713664,Predicted intracellular proteins,Evidence at protein level,HPA055744,Enhanced,,,,"Renal cancer:8.76e-6 (favourable), Pancreatic cancer:4.84e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 192.4;small intestine: 348.5,rectum: 152.0,Cell line enhanced,,BEWO: 108.3;RPTEC TERT1: 108.5
104,PRR15L,"ATAD4, MGC11242",ENSG00000167183,Proline rich 15 like,17,47951967-47957878,Predicted intracellular proteins,Evidence at protein level,HPA022918,Approved,,Approved,Cytosol,"Renal cancer:6.29e-13 (favourable), Stomach cancer:1.69e-5 (favourable)",Mixed,Tissue enhanced,,duodenum: 180.5,small intestine: 141.6,Cell line enhanced,,HaCaT: 18.3;MCF7: 15.0;SCLC-21H: 13.8;SK-BR-3: 26.8;T-47d: 22.7
105,PTPRH,SAP-1,ENSG00000080031,"Protein tyrosine phosphatase, receptor type H",19,55181248-55209506,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA042300,,,Approved,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 68.9;small intestine: 77.0,gallbladder: 38.6,Cell line enhanced,,HHSteC: 10.1;K-562: 13.5;SK-MEL-30: 17.2
106,R3HDML,dJ881L22.3,ENSG00000101074,R3H domain containing like,20,44336986-44351235,Predicted secreted proteins,Evidence at protein level,HPA070264,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 2.2;small intestine: 2.7,testis: 0.8,Not detected,,
107,REG1B,"PSPS2, REGH, REGI-BETA, REGL",ENSG00000172023,Regenerating family member 1 beta,2,79085030-79088019,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA045549, HPA045579",Supported,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 734.2;small intestine: 435.2,pancreas: 181.6,Cell line enhanced,,EFO-21: 6.0;HDLM-2: 3.9;U-2 OS: 15.6;U-251 MG: 3.2
108,RNF186,FLJ20225,ENSG00000178828,Ring finger protein 186,1,19814029-19815278,Predicted membrane proteins,Evidence at protein level,"HPA034547, HPA035558",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 132.4;epididymis: 82.2;small intestine: 46.5,kidney: 26.2,Cell line enhanced,,RPMI-8226: 1.2
109,RP11-407N17.3,,ENSG00000258941,CTAGE family member 5 isoform 8 precursor ,14,39233902-39350423,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922, HPA054066, HPA055459",Uncertain,,Approved,Endoplasmic reticulum,,Not detected,Tissue enhanced,,duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5,kidney: 19.0,Cell line enhanced,,CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0
110,RP11-697E2.12,,ENSG00000275674,,15,90266317-90314499,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,duodenum: 1.2,"cerebral cortex,small intestine: 0.8",Cell line enhanced,,BEWO: 1.8
111,RP13-1032I1.10,,ENSG00000262660,,17,81703371-81720539,Predicted intracellular proteins,Evidence at protein level,"HPA022853, HPA023043, HPA023048",Approved,,Enhanced,Mitochondria,,Not detected,Tissue enhanced,,duodenum: 2.1,cerebral cortex: 1.1,Cell line enhanced,,MOLT-4: 14.1
112,RP13-672B3.2,,ENSG00000256632,,12,132688049-132714912,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,duodenum: 2.6,"kidney,small intestine,testis: 0.6",Cell line enhanced,,REH: 1.1;U-698: 1.0
113,RXFP4,"GPCR142, GPR100, RLN3R2, RXFPR4",ENSG00000173080,Relaxin/insulin like family peptide receptor 4,1,155941710-155942949,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,colon: 2.0;duodenum: 1.4;rectum: 2.2,small intestine: 1.1,Not detected,,
114,SCTR,,ENSG00000080293,Secretin receptor,2,119439843-119525301,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA007269,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 26.7;lung: 12.7;pancreas: 14.4,stomach: 4.1,Cell line enhanced,,Karpas-707: 2.2
115,SDCBP2,"SITAC18, ST-2",ENSG00000125775,Syndecan binding protein 2,20,1309909-1329239,Predicted intracellular proteins,Evidence at protein level,"HPA054554, HPA064490",Enhanced,,Approved,Vesicles<br>Cytosol,"Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable)",Expressed in all,Tissue enhanced,,duodenum: 135.1;small intestine: 143.9,stomach: 94.5,Cell line enhanced,,CAPAN-2: 16.0
116,SEC16B,"LZTR2, PGPR-p117, RGPR, Sec16S",ENSG00000120341,"SEC16 homolog B, endoplasmic reticulum export factor",1,177923956-177984303,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054292, HPA072913",Enhanced,,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Actin filaments,,Not detected,Tissue enhanced,,duodenum: 28.2;small intestine: 30.9,liver: 18.8,Cell line enhanced,,CAPAN-2: 6.3;EFO-21: 5.1;HDLM-2: 5.3
117,SFRP5,SARP3,ENSG00000120057,Secreted frizzled related protein 5,10,97766751-97771952,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 30.9;pancreas: 31.2;small intestine: 29.4,adrenal gland: 12.9,Cell line enhanced,,A549: 2.3;CACO-2: 10.5;RPMI-8226: 3.2;SCLC-21H: 2.4
118,SH2D6,FLJ35993,ENSG00000152292,SH2 domain containing 6,2,85418721-85437029,Predicted intracellular proteins,Evidence at transcript level,HPA053873,Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 1.5;testis: 3.1;thyroid gland: 1.4,small intestine: 1.1,Cell line enhanced,,LHCN-M2: 1.7
119,SLC13A2,NaDC-1,ENSG00000007216,Solute carrier family 13 member 2,17,28473293-28497781,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014963,Enhanced,,,,Renal cancer:9.00e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 68.7;small intestine: 54.3,kidney: 19.7,Not detected,,
120,SLC22A18,"BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5",ENSG00000110628,Solute carrier family 22 member 18,11,2899721-2925246,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA067812, HPA071461",Enhanced,,,,,Expressed in all,Tissue enhanced,,duodenum: 43.2;small intestine: 31.7,colon: 10.3,Cell line enhanced,,CAPAN-2: 28.3;Karpas-707: 21.3
121,SLC22A18AS,"BWR1B, BWSCR1B, ORCTL2S, p27-BWR1B, SLC22A1LS",ENSG00000254827,Solute carrier family 22 member 18 antisense,11,2887780-2903740,Predicted intracellular proteins,Evidence at protein level,HPA068288,Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,colon: 14.4;duodenum: 13.5,small intestine: 11.0,Cell line enhanced,,A549: 8.7;CAPAN-2: 8.3;MCF7: 14.0;SK-MEL-30: 26.1;WM-115: 14.7
122,SLC25A34,DKFZp781A10161,ENSG00000162461,Solute carrier family 25 member 34,1,15736405-15741396,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA069806,,,Supported,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 14.5;small intestine: 15.2,skeletal muscle: 8.2,Mixed,,
123,SLC26A3,"CLD, DRA",ENSG00000091138,Solute carrier family 26 member 3,7,107765467-107803225,"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA036055,Approved,,,,,Tissue enriched,Tissue enhanced,,colon: 1075.0;duodenum: 577.9;rectum: 961.7,seminal vesicle: 185.8,Cell line enhanced,,RPMI-8226: 1.9
124,SLC28A2,"CNT2, HCNT2, HsT17153, SPNT1",ENSG00000137860,Solute carrier family 28 member 2,15,45252230-45277845,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046068, HPA055623",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 64.9;rectum: 37.1;small intestine: 97.9,stomach: 21.0,Not detected,,
125,SLC2A5,GLUT5,ENSG00000142583,Solute carrier family 2 member 5,1,9035107-9088478,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA005449,Enhanced,,,,Renal cancer:5.44e-5 (unfavourable),Group enriched,Tissue enhanced,,duodenum: 109.0;small intestine: 92.6;testis: 139.9,bone marrow: 64.4,Cell line enhanced,,Daudi: 134.4;U-266/70: 111.0;U-698: 121.2;U-937: 52.9
126,SLC30A10,"DKFZp547M236, ZnT-10, ZNT8, ZRC1",ENSG00000196660,Solute carrier family 30 member 10,1,219685427-219958647,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA064547,Enhanced,,,,,Tissue enriched,Tissue enhanced,,duodenum: 2.1;liver: 2.3,testis: 1.2,Cell line enhanced,,HEK93: 1.2
127,SLC44A4,"C6orf29, CTL4, FLJ14491, NG22, TPPT",ENSG00000204385,Solute carrier family 44 member 4,6,31863192-31879046,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA046977, HPA054176",Enhanced,,,,"Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable)",Tissue enhanced,Tissue enhanced,,duodenum: 35.1,colon: 28.7,Cell line enhanced,,Hep G2: 1.0
128,SLC4A7,"NBC3, SBC2, SLC4A6",ENSG00000033867,Solute carrier family 4 member 7,3,27372721-27484420,"Predicted membrane proteins, Transporters",Evidence at protein level,"CAB022494, HPA035857",Enhanced,,Supported,Plasma membrane<br>Focal adhesion sites<br>Cytosol,Renal cancer:7.91e-6 (unfavourable),Expressed in all,Tissue enhanced,,duodenum: 57.7,breast: 23.8,Expressed in all,,
129,SLC51A,OSTalpha,ENSG00000163959,Solute carrier family 51 alpha subunit,3,196211487-196243178,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA039123,Enhanced,,,,Liver cancer:7.54e-4 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 29.3;liver: 35.1;small intestine: 71.3,colon: 9.9,Cell line enhanced,,REH: 3.4
130,SLC51B,OSTbeta,ENSG00000186198,Solute carrier family 51 beta subunit,15,65045370-65053396,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA008398, HPA008533",Enhanced,,Approved,Vesicles<br>Mitochondria,Renal cancer:8.46e-5 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 59.7;duodenum: 85.4;small intestine: 118.4",colon: 40.7,Group enriched,9.0,CACO-2: 15.0;EFO-21: 11.0;Hep G2: 10.4
131,SLC6A20,"XT3, Xtrp3",ENSG00000163817,Solute carrier family 6 member 20,3,45755450-45796535,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA029873,Uncertain,,,,Renal cancer:1.55e-5 (favourable),Mixed,Tissue enhanced,,duodenum: 24.4;small intestine: 19.3,gallbladder: 10.9,Cell line enhanced,,HaCaT: 1.5
132,SMPD3,NSMASE2,ENSG00000103056,Sphingomyelin phosphodiesterase 3,16,68358325-68448688,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033885, HPA065535, HPA069383",Approved,,Supported,Endoplasmic reticulum,"Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 61.0;small intestine: 62.9,stomach: 22.6,Cell line enhanced,,HMC-1: 8.5;MOLT-4: 11.7;RPMI-8226: 8.3;SCLC-21H: 15.6
133,SOWAHA,ANKRD43,ENSG00000198944,Sosondowah ankyrin repeat domain family member A,5,132813587-132816797,Predicted secreted proteins,Evidence at protein level,HPA064621,Approved,,,,"Renal cancer:9.38e-5 (favourable), Pancreatic cancer:4.03e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 39.7;small intestine: 46.6,cerebral cortex: 22.1,Group enriched,8.0,SCLC-21H: 17.0;T-47d: 32.7
134,SST,SMST,ENSG00000157005,Somatostatin,3,187668906-187670399,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB000075, HPA019472, CAB034105",Enhanced,Supported,,,Endometrial cancer:1.93e-5 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 211.9;duodenum: 376.3;stomach: 305.7,small intestine: 142.4,Group enriched,5.0,EFO-21: 20.9;U-2 OS: 42.8
135,SSTR1,,ENSG00000139874,Somatostatin receptor 1,14,38207999-38213067,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA031506,Approved,,,,Renal cancer:4.28e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 13.6;duodenum: 14.2;stomach: 21.4,small intestine: 9.1,Cell line enhanced,,BJ: 102.5;BJ hTERT+: 27.1;fHDF/TERT166: 56.0
136,SSUH2,"C3orf32, fls485, ssu-2",ENSG00000125046,Ssu-2 homolog (C. elegans),3,8619400-8745040,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049777,Approved,,,,,Mixed,Tissue enhanced,,duodenum: 4.2;small intestine: 3.9;testis: 4.0,spleen: 1.5,Cell line enriched,13.0,Hep G2: 18.2
137,SULT1A2,"HAST4, STP2",ENSG00000197165,Sulfotransferase family 1A member 2,16,28591943-28597109,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 49.2;small intestine: 49.2,liver: 21.0,Cell line enhanced,,BEWO: 9.6;EFO-21: 12.0;Hep G2: 33.5
138,SULT1A4,,ENSG00000213648,Sulfotransferase family 1A member 4,16,29459889-29464976,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA049500, HPA051051",Supported,,,,,Not detected,Tissue enhanced,,duodenum: 173.4;small intestine: 131.0,colon: 38.4,Cell line enhanced,,CAPAN-2: 107.9;EFO-21: 93.9;HEL: 76.5;Hep G2: 188.0;Karpas-707: 114.2
139,TGFBR3L,,ENSG00000260001,Transforming growth factor beta receptor 3 like,19,7916145-7919097,Predicted membrane proteins,Evidence at protein level,HPA074356,Supported,,Approved,Vesicles,,Mixed,Tissue enhanced,,duodenum: 1.7;small intestine: 1.8,kidney: 1.0,Cell line enhanced,,PC-3: 3.7;REH: 9.0
140,TJP3,ZO-3,ENSG00000105289,Tight junction protein 3,19,3708109-3750813,Predicted intracellular proteins,Evidence at protein level,"CAB013244, HPA046863, HPA053337",Enhanced,,Enhanced,Nucleoplasm<br>Cell Junctions,"Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 41.5;small intestine: 41.3,colon: 30.6,Cell line enhanced,,BEWO: 42.4;CAPAN-2: 39.5;SK-BR-3: 19.4;T-47d: 51.5
141,TLDC2,"C20orf118, dJ132F21.2",ENSG00000101342,TBC/LysM-associated domain containing 2,20,36876121-36894235,Predicted intracellular proteins,Evidence at transcript level,HPA047468,Approved,,,,Renal cancer:9.97e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,duodenum: 19.0;small intestine: 20.1,rectum: 13.3,Cell line enriched,10.0,HMC-1: 30.5
142,TMC4,,ENSG00000167608,Transmembrane channel like 4,19,54160108-54173250,Predicted membrane proteins,Evidence at protein level,HPA048635,Approved,,,,Renal cancer:1.54e-8 (favourable),Expressed in all,Tissue enhanced,,duodenum: 30.8,small intestine: 22.1,Cell line enriched,7.0,T-47d: 27.9
143,TMEM139,FLJ90586,ENSG00000178826,Transmembrane protein 139,7,143279957-143288048,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036982, HPA036983",Approved,,Approved,Plasma membrane<br>Focal adhesion sites,"Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 34.0;kidney: 34.6,small intestine: 20.7,Cell line enhanced,,CAPAN-2: 35.7;EFO-21: 26.3;RPTEC TERT1: 53.2;T-47d: 64.1
144,TMEM150B,"TMEM224, TTN2",ENSG00000180061,Transmembrane protein 150B,19,55312801-55334048,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:6.14e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,duodenum: 69.8;small intestine: 66.5,lung: 18.9,Cell line enhanced,,CACO-2: 7.6;HMC-1: 4.0;U-937: 16.3
145,TMEM229A,,ENSG00000234224,Transmembrane protein 229A,7,124030916-124033023,Predicted membrane proteins,Evidence at protein level,HPA056391,Uncertain,,Approved,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 7.1;duodenum: 8.6;testis: 10.4,small intestine: 4.4,Cell line enriched,46.0,SH-SY5Y: 141.7
146,TMEM45B,"BC016153, FLJ40787",ENSG00000151715,Transmembrane protein 45B,11,129815819-129860003,Predicted membrane proteins,Evidence at protein level,HPA015878,Approved,,Uncertain,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,duodenum: 136.2;small intestine: 139.1,rectum: 103.3,Cell line enhanced,,CACO-2: 32.2;Hep G2: 27.4;PC-3: 45.6;RT4: 105.7;T-47d: 34.7
147,TMEM82,,ENSG00000162460,Transmembrane protein 82,1,15742422-15747982,Predicted membrane proteins,Evidence at protein level,HPA060282,Uncertain,,Uncertain,Nucleoplasm<br>Cytosol,Renal cancer:3.80e-7 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 23.0;liver: 9.0;small intestine: 19.4,kidney: 7.6,Cell line enriched,5.0,CACO-2: 2.6
148,TMEM92,FLJ33318,ENSG00000167105,Transmembrane protein 92,17,50271406-50281485,Predicted membrane proteins,Evidence at protein level,"HPA063009, HPA069820",Approved,,Supported,Nucleoplasm,"Renal cancer:1.14e-6 (unfavourable), Head and neck cancer:8.35e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 40.2;small intestine: 50.6,gallbladder: 21.8,Cell line enhanced,,A549: 16.5;CACO-2: 25.7;CAPAN-2: 25.7;EFO-21: 56.2
149,TNFRSF11A,"CD265, FEO, LOH18CR1, PDB2, RANK",ENSG00000141655,TNF receptor superfamily member 11a,18,62325287-62391292,"CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB010391, HPA027728, HPA047976",Uncertain,,Supported,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,duodenum: 30.6,small intestine: 20.5,Cell line enhanced,,HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0
150,TPSG1,"PRSS31, TMT",ENSG00000116176,Tryptase gamma 1,16,1221651-1225257,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA060458,Enhanced,,,,Renal cancer:1.76e-8 (unfavourable),Tissue enhanced,Tissue enhanced,,colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5,ovary: 2.5,Group enriched,8.0,HMC-1: 20.4;MCF7: 6.0
151,TREH,"MGC129621, TRE, TREA",ENSG00000118094,Trehalase,11,118657316-118679690,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA039913, HPA042045",Enhanced,,,,"Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)",Mixed,Tissue enhanced,,duodenum: 60.6;small intestine: 72.6,kidney: 13.5,Cell line enhanced,,BEWO: 1.5
152,TRIM15,"RNF93, ZNF178, ZNFB7",ENSG00000204610,Tripartite motif containing 15,6,30163206-30172696,Predicted intracellular proteins,Evidence at protein level,HPA047527,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,colon: 2.6;duodenum: 3.6,"appendix,small intestine: 1.1",Cell line enriched,24.0,HEL: 15.2
153,TSPAN8,"CO-029, TM4SF3",ENSG00000127324,Tetraspanin 8,12,71125085-71441898,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,"CAB026009, HPA044337",Enhanced,,Approved,Nucleoplasm,"Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,colon: 910.6;duodenum: 905.9;rectum: 911.5;small intestine: 909.2,stomach: 573.4,Cell line enhanced,,CACO-2: 36.0;HeLa: 34.8;PC-3: 151.7;RT4: 30.6
154,TUBAL3,FLJ21665,ENSG00000178462,Tubulin alpha like 3,10,5393098-5404830,Predicted intracellular proteins,Evidence at protein level,"HPA045900, HPA063394",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 24.4;small intestine: 31.0,colon: 11.8,Group enriched,6.0,HEL: 11.9;K-562: 3.8
155,UCN3,"SPC, UCNIII",ENSG00000178473,Urocortin 3,10,5365009-5374692,Predicted secreted proteins,Evidence at protein level,HPA038281,Uncertain,,,,,Group enriched,Tissue enhanced,,duodenum: 9.3;small intestine: 7.5,stomach: 3.6,Cell line enriched,10.0,SCLC-21H: 1.5
156,UGT1A10,UGT1J,ENSG00000242515,UDP glucuronosyltransferase family 1 member A10,2,233636454-233773305,"Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Pancreatic cancer:4.55e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,colon: 49.7;duodenum: 80.9;small intestine: 59.1,rectum: 39.6,Cell line enriched,108.0,RT4: 416.9
157,UGT2A3,FLJ21934,ENSG00000135220,UDP glucuronosyltransferase family 2 member A3,4,68928463-68951791,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,"Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9,rectum: 23.9,Cell line enriched,8.0,Hep G2: 13.5
158,UGT2B17,,ENSG00000197888,UDP glucuronosyltransferase family 2 member B17,4,68537184-68568527,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,,Group enriched,Tissue enhanced,,colon: 372.4;duodenum: 371.2;small intestine: 522.5,rectum: 151.7,Cell line enhanced,,RPMI-8226: 1.2
159,UNC5CL,"MGC34763, ZUD",ENSG00000124602,Unc-5 family C-terminal like,6,41026911-41039217,Predicted intracellular proteins,Evidence at protein level,HPA015725,Enhanced,,Approved,Centrosome,,Mixed,Tissue enhanced,,duodenum: 37.3;small intestine: 32.4;stomach: 23.8,kidney: 15.0,Cell line enhanced,,CACO-2: 5.8;RPTEC TERT1: 10.0
160,UNC5D,"KIAA1777, Unc5h4",ENSG00000156687,Unc-5 netrin receptor D,8,35235457-35796550,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042940,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.2;duodenum: 6.1;prostate: 8.3,"cervix, uterine: 3.4",Cell line enhanced,,HEK93: 2.7;NTERA-2: 9.6;SH-SY5Y: 3.5;U-251 MG: 2.5
161,UNC93A,"dJ366N23.1, dJ366N23.2",ENSG00000112494,Unc-93 homolog A (C. elegans),6,167271169-167316019,Predicted membrane proteins,Evidence at protein level,HPA035729,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 9.7;liver: 7.1;skin: 17.8,esophagus: 5.6,Group enriched,9.0,CACO-2: 6.1;Hep G2: 2.1;SCLC-21H: 3.7
162,USH1C,"AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C",ENSG00000006611,USH1 protein network component harmonin,11,17493895-17544416,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB013690, HPA027398, HPA027492, HPA028033",Supported,,Enhanced,Cytosol,"Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable)",Group enriched,Tissue enhanced,,duodenum: 99.2;small intestine: 106.9,kidney: 55.4,Cell line enhanced,,CACO-2: 50.5;CAPAN-2: 7.4;HeLa: 14.4
163,XDH,"XO, XOR",ENSG00000158125,Xanthine dehydrogenase,2,31334321-31414715,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA062641, HPA069323",Supported,,Supported,Nucleus,Urothelial cancer:8.73e-6 (favourable),Mixed,Tissue enhanced,,breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6,colon: 11.2,Cell line enhanced,,HBEC3-KT: 14.4;hTERT-HME1: 23.9
164,ZNF511-PRAP1,,ENSG00000283496,ZNF511-PRAP1 readthrough,10,133309410-133352529,Predicted membrane proteins,Evidence at protein level,"HPA035360, HPA038713, HPA052451",Supported,,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,,,Tissue enhanced,,duodenum: 25.2;small intestine: 25.0,kidney: 10.7,Cell line enhanced,,Hep G2: 11.3
